This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Merck Adds HCV Candidates with Idenix Buy

NEW YORK (The Deal) -- Merck (MRK) is making an all-cash $3.85 billion tender offer for Cambridge, Mass.-based Idenix Pharmaceuticals (IDIX), in a strategic bid to strengthen Merck's hepatitis C drug program.

Roger Perlmutter, president, Merck Research Laboratories, laid out the strategic basis for the deal in a nutshell: "Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside/nucleotide chemistry and prodrug technologies. Idenix's investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all-oral, ribavirin-free, pan-genotypic regimen that has duration of treatment as short as possible for millions of patients in need around the world."

The deal, announced Monday and already approved by the boards of Merck and Idenix, must pass muster with regulatory authorities and is expected to close in the third quarter.

Merck said it projects the HCV market to top $20 billion by 2018, based on data from research group EvaluatePharma.

Merck will pay $24.50 in cash per share of Idenix stock.

The announcement made for quite a pop in Idenix shares. They ended trading Friday at $7.23 and prices soared nearly 232%, trading at $24 in New York Monday morning.

Idenix specializes in developing nucleosides and nucleotides, or nucs. It claims a large patent estate in those compounds. "Nucs are scarce and thus perhaps quite valuable" noted ISI Group biotechnology/pharma analyst Mark Schoenebaum. "Part of Merck's purchase price almost certainly applied some kind of value to Idenix's patent portfolio," he wrote in a same-day note.

Gilead's newly approved $1,000-a-pill HCV treatment Sovalidi (sofosbuvir) is a nucleotide analog.

Idenix has three HCV drug candidates in clinical development, with the most important to Merck being IDX21437, a nucleotide prodrug. The triad includes another nucleotide prodrug, IDX21459, and an NS5a inhibitor.

HCV is an emerging epidemic, affecting 130 million to 150 million individuals across the globe, according to the World Health Organization. In the U.S., the number affected is around 3 million to 4 million. As many as half a million die each year from the disease. Because the virus can be silent for decades, a large percentage of those infected do not know they are.

Credit Suisse AG provided financial advice to Merck. The buyer turned to a team at Hughes Hubbard & Reed LLP for legal advice led by James Modlin, David Schwartz, Andrew Braiterman, Alexander Anderson, Sarah Downie, Ethan Litwin, William Kolasky, Alain Vincent, Nadine Voisin, Stefan Naumann, counsel Cyrille Gaucher and associates Julie Thorston, Justin Greenbaum, Christine Lamsvelt and Erin deCecchis.

Idenix used Centerview Partners for financial advice and Sullivan & Cromwell LLP for legal advice. The Sullivan & Cromwell team included Frank Aquila, Krishna Veeraraghavan, Ronald Creamer Jr., Matthew Friestedt, Nader Mousavi, special counsel Spencer Simon and associates Brenden Rowook Park, Mark Campbell, Julia Kim, Jeffrey Arbeil, Jeannett Braun and Jennifer Yoon.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.87 -116.81 -0.68%
S&P 500 1,982.77 -11.52 -0.58%
NASDAQ 4,508.6880 -19.0010 -0.42%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs